800 results on '"Mitchell, Duane A."'
Search Results
202. The History, Evolution, and Clinical use of Dendritic Cell-Based Immunization Strategies in the Therapy of Brain Tumors
203. Immunotherapy of brain tumors
204. Immunotherapy of High-Grade Gliomas: Preclinical In Vivo Experiments in Animal Models
205. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma
206. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma
207. Chasing cancer with chimeric antigen receptor therapy
208. Adult precision medicine: learning from the past to enhance the future
209. Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
210. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial
211. Nanoparticles as immunomodulators and translational agents in brain tumors
212. Abstract A18: Personalized RNA nanoparticles remodel the HNSCC immunologic milieu to unlock immunotherapeutic activity
213. Tracking Adoptive T Cell Therapy Using Magnetic Particle Imaging
214. Adult immuno-oncology: using past failures to inform the future
215. Abstract B83: RNA-nanoparticles for immunotherapy-resistant head and neck squamous cell carcinoma
216. Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity
217. Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma
218. RNA-electroporated T cells for cancer immunotherapy
219. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas
220. Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging
221. ATIM-34. SINGLE-CELL RNA SEQUENCING REVEALS DYNAMIC IMMUNE RESPONSE CHANGES IN GLIOBLASTOMA PATIENT WITH DURABLE COMPLETE RESPONSE TO CMV PP65-LAMP RNA-PULSED DENDRITIC VACCINES
222. IMMU-05. DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA
223. IMMU-25. MAGNETIC PARTICLE IMAGING FOR NON-INVASIVE TRACKING OF ADOPTIVE CELL TRANSFER IN CANCER IMMUNOTHERAPY
224. TMOD-07. IN SITU MICROSCOPY OF DRUG AND IMMUNE CELL INTERACTIONS AGAINST BIOFABRICATED TUMOR MODELS
225. IMMU-39. RNA LOADED LIPID-NANOPARTICLES FUNCTION AS CUSTOMIZABLE IMMUNOTHERAPEUTIC VEHICLES AGAINST MALIGNANT GLIOMAS
226. TMIC-50. 3D QUANTIFICATION OF DYNAMIC CYTOKINE GRADIENTS PRODUCED BY PRIMARY TUMOR MODELS
227. IMMU-15. A UNIQUE SELF-STIMULATIVE PROPERTY OF CD70 CAR ADVANCES T CELL FUNCTION AND ANTI-TUMOR RESPONSE IN GLIOBLASTOMA
228. IMMU-49. THE SELECTIVE ENRICHMENT OF T CELLS TARGETING UNKNOWN BRAIN CANCER ANTIGENS VIA TROGOCYTOSIS
229. IMMU-32. RNA-NANOPARTICLE VACCINES MEDIATE T CELL TRAFFICKING NECESSARY FOR BBB PASSAGE AND ANTI-GLIOMA IMMUNE RESPONSE
230. IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS
231. IMMU-24. A COMPREHENSIVE IN SILICO APPROACH TO DISCOVERING TUMOR REJECTION ANTIGENS IN MALIGNANT BRAIN TUMORS
232. EXTH-42. QUANTITATIVE BIODISTRIBUTION OF ADOPTIVELY TRANSFERRED T CELLS IN BRAIN TUMOR-BEARING MICE
233. TMIC-49. ABROGATING CD70 EXPRESSION IN GBM RESULTS IN A REDUCED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT
234. IMMU-07. CELLULAR IMMUNOTHERAPY TO OVERCOME TEMOZOLOMIDE INDUCED T CELL EXHAUSTION IN GLIOBLASTOMA
235. TMIC-29. METABOLIC INTERACTIONS BETWEEN TREATMENT-RESISTANT SLOW-CYCLING CELLS AND THE IMMUNE SYSTEM IN HIGH-GRADE GLIOMA
236. IMMU-41. RNA-MODIFIED T CELLS AS PROFESSIONAL ANTIGEN PRESENTING CELLS
237. TMIC-08. IDENTIFICATION OF TUMOR SPECIFIC LYMPHOCYTES IN A MURINE GLIOMA MODEL
238. IMMU-13. MECHANISMS OF IMMUNOLOGICAL ESCAPE DURING ADOPTIVE CELLULAR THERAPY IN HIGH GRADE GLIOMA
239. ATIM-15. SUSTAINED COMPLETE RADIOGRAPHIC RESPONSE AND PROLONGED SYSTEMIC IMMUNE ACTIVATION IN A PATIENT WITH MGMT UNMETHYLATED MIDLINE GLIOBLASTOMA RECEIVING CMV pp65-LAMP RNA-PULSED DENDRITIC CELL VACCINES
240. IMMU-26. RADIATION AND TEMOZOLOMIDE UP-REGULATES CD70 EXPRESSION AND ENHANCES CAR T- CELL RECOGNITION IN GBM
241. IMMU-27. IMMUNE CHECKPOINT BLOCKADE OF EX VIVO EXPANDED T CELLS FOR USE IN ADOPTIVE CELLULAR THERAPY (ACT) FOR GLIOBLASTOMA
242. EXTH-15. INCREASING THE TRAFFICKING OF DENDRITIC CELLS VIA CXC CHEMOKINE SIGNALING PATHWAY LEADS TO IMPROVED ANTI-TUMOR EFFICACY OF DENDRITIC CELL VACCINES
243. EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
244. CD70 CXCR2-Modified CAR T-Cells Against Acute Myeloid Leukemia
245. Immunotherapy of malignant brain tumors
246. MOESM1 of Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
247. Comment on Mahajan, S.; Schmidt, M.H.H. Distinct Lineage of Slow-Cycling Cells Amidst the Prevailing Heterogeneity in Glioblastoma. Cancers 2023, 15 , 3843.
248. RNA-transfected dendritic cells in cancer immunotherapy
249. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
250. Identification of Tumor Specific Lymphocytes Cells in a Murine Glioma Model
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.